Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial

The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.

Prana Biotechnology Ltd. is set to proceed straight to a pivotal trial of its Huntington’s disease candidate PBT2 after the drug hit just one of many efficacy endpoints in its first Phase II study, Reach2HD.

Prana’s PBT2 is the company’s lead metal protein-attenuating compound aimed at neurodegenerative diseases. The company’s “MPACs” are based on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D